Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention

PharmacoEconomics

Volumn 25, Issue 9, 2007, Pages 769-782

  Heeg, Bart M S ^a   Peters, Ron J G ^b   Botteman, Marc ^c   Van Hout, Ben A ^a  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c PHARMERIT INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEATH; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONG TERM CARE; MORTALITY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK MANAGEMENT; RISK REDUCTION; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; TICLOPIDINE;

EID: 34748862584     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725090-00005     Document Type: Article

References (37)

1. Mehta S, Yusuf S, Peters R, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33
2. Steinhubl S, Berger P, Mann III J, et al. Early sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002; 288: 2411-20
3. The Dutch Institute for Healthcare Improvement (CBO). Multidisciplinary guideline cardiovascular risk management. Utrecht: The Dutch Institute for Healthcare Improvement (CBO), 2006
4. The Dutch Institute for Healthcare Improvement (CBO). Treatment and prevention of coronary heart disease by lowering plasma cholesterol levels. Utrecht: The Dutch Institute for Healthcare Improvement (CBO), 1998
5. Task force Revised guidelines Hypertension. Revised guidelines hypertension. Utrecht: The Dutch Institute for Healthcare Improvement (CBO), 2000
6. Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-39
7. Heeg BMS, van Gestel A, van Hout BA, et al. Costs and effects of clopidogrel versus aspirin in high-risk acute coronary syndrome patients in Denmark. Ugeskrift for Læger 2006; 168: 2911-5
8. College voor Zorgverzekeringen. Dutch guidelines for pharmacoeconomic research. Amstelveen: College voor Zorgverzekeringen, 1999
9. Central Bureau of Statistics. Statline [online]. Available from URL: www.CBS.nl [Accessced 2007 Aug 9]
10. Peeters A, Mamun A, Willekens F, et al. A life course analysis of the original Framingham heart study cohort. Eur Heart J 2002; 23: 458-66
11. Hollander D, Koudstraal P, Bots M, et al. Incidence, risk, and case fatality of first ever stroke in the elderly population: the Rotterdam Study. J Neurol Neurosurg Psychiatry 2003; 74: 317-21
12. Koek HL, de BA, Gast F, et al. Short- and long-term prognosis after acute myocardial infarction in men versus women. Am J Cardiol 2006 Oct 15; 98 (8): 993-9
13. The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
15. Caro J, Migliaccio-Walle K, for the CAPRA study group. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. Am J Med 1999; 107: 568-72
16. de Boer MJ, Lee Liem A, Suryapranata H, et al. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol 1995; 76: 830-3
17. Niessen LW, Dippel DW, Limburg M. Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline 'Stroke'. Ned Tijdschr Geneeskd 2000; 144: 1959-64
18. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673-81
19. College voor Zorgverzekeringen. Farmacotherapeutisch Kompas 2004. Amstelveen: CVZ, 2004
20. Hiatt MD. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardiol infarction: a decision analysis. Cardiology 1999; 91: 243-9
21. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993; 13: 161-5
22. Mark D, Hlatky M, Califf R, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24
23. Lee TT, Solomon N, Heidenreich PA, et al. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997; 126: 337-46
24. Hallan S, Asberg A, Indredavik B, et al. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med 1999; 246: 309-16
25. Prismant. Hospital statistics [online]. Available from URL: www.prismant.nl [Accessed 2007 Aug 9]
26. Doubilet P, Begg C, Weinstein M, et al. Probabilistic senstivity analyses using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5: 157-77
27. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
28. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited. Eur Heart J 2004; 25: 720-2
29. van Luijn JCF. Farmacoeconomic report clopidogrel (Plavix). Amstelveen: Dutch Healthcare Insurance board, 2004
30. van Hout BA, Tangelder M, Bervouts P, et al. Cost-effective ness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation in the Netherlands [abstract]. Value Health 2003; 6: 667
31. Lindgren P, J̈onsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J Int Med 2004; 255: 562-70
32. Annemans L, Lindgren P, Frei A, et al. Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing percutaneous coronary interventions: a five European countries analysis [abstract]. Eur Heart J 2003; 24: Suppl.: 130
33. Lindgren P, Stenestrand U, Malmberg K, et al. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther 2005; 27: 100-10
34. Weintraub WS, Mahoney EM, Mehta S, et al. Long-term cost-effectiveness of clopidogrel in patients having percutaneous coronary intervention early after acute coronary syndrome: results from PCI-CURE [abstract 1137-77]. J Am Coll Cardiol 2004; 43 Suppl. 2: A296
35. Cowper P, Udayakumar K, Sketch M, et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol 2005; 45: 369-76
36. Ringborg A, Lindgren P, Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ 2005 Dec; 6 (4): 354-62
37. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 4: 2126-30